E Fund Management Co. Ltd. Has $1.65 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

E Fund Management Co. Ltd. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,315 shares of the biopharmaceutical company’s stock after selling 569 shares during the period. E Fund Management Co. Ltd.’s holdings in Gilead Sciences were worth $1,646,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Tompkins Financial Corp increased its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC bought a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. Rakuten Securities Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $33,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at $40,000. 83.67% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the transaction, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GILD. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Maxim Group cut their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. TD Cowen cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Finally, UBS Group lowered their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $83.69.

Gilead Sciences Stock Down 0.5 %

NASDAQ GILD traded down $0.34 during trading hours on Thursday, hitting $64.58. The company’s stock had a trading volume of 6,023,221 shares, compared to its average volume of 7,413,408. The company has a market capitalization of $80.41 billion, a PE ratio of 179.39, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86. The company’s 50-day simple moving average is $70.09 and its two-hundred day simple moving average is $75.52.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $1.37 earnings per share. Research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.77%. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.